Results 151 to 160 of about 2,530 (165)

Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD. [PDF]

J Vitreoretin Dis
Stevanovic M, Koulisis N, Chen T, Moysidis SN, Burkemper B, Toy BC, Rao NA, Eliott D, Humayun MS.   +8 more
europepmc   +1 more source

Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema. [PDF]

Jpn J Ophthalmol
Hirano T, Chiku Y, Hoshiyama K, Takahashi Y, Ito S, Murata T.   +5 more
europepmc   +1 more source

Management of Polypoidal choroidal vasculopathy and diabetic retinopathy: Practice patterns amongst vitreoretinal surgeons of India-A VRSI survey. [PDF]

Indian J Ophthalmol
Sindal MD, Mahendrakar P, Kothari A, Tyagi M, Mishra D, Tagare S, Vaidya M, Shanmugam M.   +7 more
europepmc   +1 more source

Initial Response After Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration. [PDF]

J Clin Med
Hara C, Fujimoto S, Fukushima Y, Sayanagi K, Nishida K, Maruyama K, Sato S, Maeno T, Nishida K.   +8 more
europepmc   +1 more source

Real-world database evaluation of drug-associated vitreous opacities and machine learning for clinical interpretability. [PDF]

Front Cell Dev Biol
Guan W, Wu SN, Feng K, Xu C, Liu Y, Yan B, Lv J, Huang C, Hu J, Liu Z.   +9 more
europepmc   +1 more source

Cost-effectiveness of anti-vascular endothelial growth factor and macular laser treatments for people with centre-involving diabetic macular oedema and central retinal thickness of at least 400 micrometres. [PDF]

Eye (Lond)
Luckham K, Tebbs H, Dadswell C, Yosef A, Claxton L, Kelley K, Taske N, Burgess PI, Dinah C, Lois N, Mohiuddin S.   +10 more
europepmc   +1 more source

Successful Response to Intravitreal Faricimab Injections in a Case of Neovascular Age-Related Macular Degeneration in Vitrectomized Eyes. [PDF]

Cureus
Chujo S, Matsubara H, Mase Y, Kato K, Kondo M.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Brolucizumab

Reactions Weekly, 2022
  +16 more sources

Brolucizumab

Reactions Weekly, 2023
  +12 more sources

Brolucizumab

Reactions Weekly
  +8 more sources